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ORIGINAL ARTICLE
Prognostic Relevance of Palliative Primary Tumor Removal
in 37,793 Metastatic Colorectal Cancer Patients
A Population-based, Propensity Score–adjusted Trend Analysis
Ignazio Tarantino, MD, MSc,∗† Rene Warschkow, MD, MSc,∗‡ Mathias Worni, MD, MHS,§¶ Thomas Cerny, MD,||
Alexis Ulrich, MD,† Bruno M. Schmied, MD, MBA,∗ and Ulrich Gu¨ller, MD, MHS§||
Objective: To assess whether palliative primary tumor resection in colorectal
cancer patients with incurable stage IV disease is associated with improved
survival.
Background: There is a heated debate regarding whether or not an asymp-
tomatic primary tumor should be removed in patients with incurable stage IV
colorectal disease.
Methods: Stage IV colorectal cancer patients were identified in the Surveil-
lance, Epidemiology, and End Results database between 1998 and 2009.
Patients undergoing surgery to metastatic sites were excluded. Overall sur-
vival and cancer-specific survival were compared between patients with and
without palliative primary tumor resection using risk-adjusted Cox propor-
tional hazard regression models and stratified propensity score methods.
Results: Overall, 37,793 stage IV colorectal cancer patients were identified.
Of those, 23,004 (60.9%) underwent palliative primary tumor resection. The
rate of patients undergoing palliative primary cancer resection decreased from
68.4% in 1998 to 50.7% in 2009 (P < 0.001). In Cox regression analysis after
propensity score matching primary cancer resection was associated with a
significantly improved overall survival [hazard ratio (HR) of death = 0.40,
95% confidence interval (CI) = 0.39–0.42, P < 0.001] and cancer-specific
survival (HR of death = 0.39, 95% CI = 0.38–0.40, P < 0.001). The benefit
of palliative primary cancer resection persisted during the time period 1998 to
2009 with HRs equal to or less than 0.47 for both overall and cancer-specific
survival.
Conclusions: On the basis of this population-based cohort of stage IV col-
orectal cancer patients, palliative primary tumor resection was associated with
improved overall and cancer-specific survival. Therefore, the dogma that an
asymptomatic primary tumor never should be resected in patients with unre-
sectable colorectal cancer metastases must be questioned.
Keywords: incurable, metastases, metastatic colorectal cancer, palliative
resection
(Ann Surg 2015;262:112–120)
O f all patients with colorectal cancer, approximately 25% presentwith metastatic disease and another 25% are likely to de-
velop metachronous metastases. Considering the prevalence of the
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disease—the third most common malignancy—metastatic colorectal
cancer represents a tremendous public health problem with more than
140,000 new colorectal cancer patients and more than 50,000 cancer
deaths estimated for 2012 in the United States.1
It is well known that removal of both primary tumor as well
as all metastatic lesions is associated with the longest overall sur-
vival. However, in many stage IV patients, complete resection is
not an option, for example, due to the extent of the disease or pro-
hibitive comorbidities. In this context, it is a matter of great debate
whether some of these patients benefit from a palliative primary
tumor resection. The main arguments in favor of resection are a
low operative morbidity and mortality for elective colorectal surgery
compared with higher complication rates in the emergency situa-
tion. Indeed, by removing the primary tumor potential problems due
to obstruction or bleeding can be avoided.2–4 Conversely, a nonop-
erative management of asymptomatic patients is associated with a
low incidence of primary tumor–related adverse events requiring a
surgical intervention.5–8 Furthermore, removing the primary tumor
may be associated with postoperative complications in some patients
precluding an early application of life-prolonging systemic therapy.9
With respect to overall and cancer-specific survival, the debate
is even more controversial.10,11 It is still unknown whether the removal
of the primary tumor without resection of distant metastases leads to
any survival benefit. Unfortunately, comparative data on outcomes of
metastatic colorectal cancer patients who did and who did not undergo
palliative primary tumor resection are scarce. Therefore, the objective
of this population-based investigation of metastatic colorectal cancer
patients in the United States was to assess whether palliative primary
tumor removal—without resection of metastases—results in an im-
proved overall and cancer-specific survival. We hypothesized that the
difference in overall and cancer-specific survival between the subsets
of patients who did and who did not undergo primary tumor resec-
tion would decrease over time because of improvement of systemic
treatment.
METHODS
Cohort Definition: Surveillance, Epidemiology,
and End Results
The recent ASCII text data version of the Surveillance, Epi-
demiology, and End Results (SEER) Program of the National Cancer
Institute in the United States, covering approximately 28% of cancer
cases in the United States, was the source of present population-
based analysis.12 SEER data were collected and reported using data
items and codes as documented by the North American Association
of Central Cancer Registries (NAACCR).13 Primary cancer site and
histology were coded according to criteria in the third edition of the
International Classification of Diseases for Oncology (ICD-O-3).14
Colorectal cancer patients were identified by the ICD-O-3 site codes
C180, C182 to C189, C199 and C209 and behavior code 3 (NAACCR
items 400 and 523). Patients diagnosed at autopsy or by death
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certificate only as well as patients without histological confirmation
were excluded (NAACCR items 490 and 2180). The analysis was
restricted to patients with adenocarcinoma identified by the ICD-O-3
histology codes 8140, 8144, 8210, 8211, 8220, 8221, 8261, 8262, and
8263 (NAACCR item 522). The following patients were excluded:
patients with other SEER reportable cancers if the colorectal ma-
lignancy was not the first diagnosed cancer (NAACCR Item 380);
patients without distant metastases (NAACCR items 790 and 2980);
patients who underwent surgical procedures of other sites than the
primary tumor (NAACCR items 1294 and 1648), patients receiving
only local tumor excision or local tumor destruction; and patients
with lacking information regarding the operation of the primary tu-
mor site (NAACCR items 1290 and 1646). The remaining patients
were grouped in 2 subsets according to whether or not a primary tumor
resection was performed (NAACCR items 1290 and 1646). Patients
who died before the recommended surgery were accounted into the
group of patients undergoing primary tumor resection (NAACCR
Item 1340) according to the intention-to-treat principle.
Statistical Analysis
Statistical analyses were performed using the R statistical soft-
ware (www.r-project.org). A 2-sided P < 0.05 was considered statisti-
cally significant. Continuous data are expressed as means ± standard
deviation.
First, χ 2 statistics were used to compare dichotomous or cat-
egorical patient characteristics. To analyze the time trends in the
prevalence of metastatic colorectal cancer and primary cancer re-
moval, Spearman’s rho was estimated. To assess putative bias of
patient characteristics for primary cancer resection, a full logistic re-
gression model was applied. Significance levels were estimated using
likelihood ratio tests, and Wald type 95% confidence intervals (CIs)
were computed. Second, resection of the primary cancer was assessed
as a prognostic factor for survival in Kaplan-Meier analysis and in
Cox regression analyses with and without risk adjustment for year
of diagnosis, age, sex, race/ethnicity, marital status, place of birth,
location of tumor, carcinoembryonic antigen level (CEA), and grad-
ing (risk set). Statistical testing was done by likelihood ratio tests
and Wald type 95% CIs were provided. The variables T-stage and
N-stage were purposefully not included in multivariable analyses as a
large fraction of patients did not undergo primary tumor resection and
thus data were not available as pathologic staging. The proportional
hazard assumption was tested by scaled Schoenfeld residuals and by
inspection of the hazard ratio (HR) plots.15 Third, a propensity score
analysis as a superior and more refined statistical method to adjust
for potential baseline confounding variables was performed.16–18 The
“MatchIt” and the “optmatch” R packages were used to perform a
bipartite weighting propensity score analysis.19,20 The distance mea-
sure was estimated by logistic regression using the risk set described
earlier with stratification for the year of diagnosis to predict pri-
mary cancer resection. Patients undergoing primary tumor resection
without a counterpart were excluded from the analysis. Afterwards,
the baseline risk profiles of the matched patients were compared to
assure that no major difference in baseline patient characteristics per-
sisted by χ 2 statistics. Fourth, the prognostic value of primary tumor
Colorectal cancer paents diagnosed 
between 1998-2009, aged 18+ years
(N=420,553)
Diagnosis not conﬁrmed by histology
(N=13,771)
Histologically conﬁrmed diagnosis
(N=406,782)
Diagnosed by autopsy or death cerﬁcate
(N=352)
Premortum cancer diagnosis
(N=406,430)
Other histology:
(N=63,760)
Adenocarcinoma histology
(N=342,670)
Not only or ﬁrst malignancy in Database
(N=66,721)
Primary colorectal cancer
(N=275,949)
No metastac disease
(N=229,737)
Metastac colorectal cancer
(N=46,212)
Surgery of distant site unreported or 
performed
(N=7,674)
No surgery of distant site
(N=38,538)
Surgery of primary site unreported or 
done as local tumor destrucon or local 
tumor excision
(N=745)
Included in analysis
( N=37,793)FIGURE 1. Flow chart of patients’ cohort
definition.
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resection for overall mortality was assessed in a Cox regression anal-
ysis using the weights and strata obtained by the bipartite matching
propensity score analysis. Statistical testing was done by likelihood
ratio tests, and Wald type 95% CIs were provided. The confirmatory
analysis was based on an intention-to-treat analysis and further veri-
fied by a per-protocol analysis, which served as a sensitivity analysis.
Finally, the computations were repeated as sensitivity analysis after
substituting unknown/undocumented data (category “Unknown” for
race/ethnicity, marital status, place of birth, and CEA and category
“Gx” for grading) using a random survival forest method.21
RESULTS
Patient Characteristics and Treatment Trend
For present investigation, 37,793 of 445,603 patients diag-
nosed with colorectal cancer between 1998 and 2009 were included
(Fig. 1). Of those, 23,004 (60.9%) patients underwent primary tumor
resection, whereas 14,789 (39.1%) did not. Table 1 summarizes the
patients’ characteristics for both groups.
Figure 2 displays the trends for the prevalence of metastatic
disease and the rate of primary cancer removal over time. The rate
of metastatic colorectal cancer continuously increased from 15.4% in
1998 to 18.1% in 2009 (P < 0.001). The rate of patients undergoing a
primary cancer resection decreased continuously from 68.4% in 1998
to 50.7% in 2009 (P < 0.001). The same trend was observed both for
patients 65 years or younger (70.6% in 1998 to 50.8% in 2009, P <
0.001) and patients older than 65 years (67.1% in 1998 to 50.6% in
2009, P < 0.001).
Primary Cancer Resection as a Prognostic Factor
for Survival
Figures 3A and 3B show Kaplan-Meier curves for overall
and cancer-specific survival in patients with and without palliative
primary tumor resection subdivided into 3 time intervals. Survival
increased for both groups during later time periods but patients with
palliative primary tumor resection consistently had a better overall
and cancer-specific survival compared with those not undergoing
surgery. Figure 3C and 3D display the trend in median overall and
cancer-specific survival for patients who did and who did not un-
dergo palliative primary tumor resection. Median overall and cancer-
specific survival significantly improved over time for both subsets.
In unadjusted Cox proportional hazards regression analysis, pallia-
tive primary tumor resection was a statistically significant protective
factor for overall (HR of death = 0.49, 95% CI = 0.48–0.50, P <
0.001) and cancer-specific survival (HR of death = 0.49, 95% CI =
0.47–0.50, P < 0.001), respectively. After multivariable risk adjust-
ing in Cox proportional hazard regression analysis, palliative primary
tumor resection had a significantly protective effect on overall sur-
vival (HR of death = 0.45, 95% CI = 0.43–0.46, P < 0.001) and
cancer-specific survival (HR of death = 0.44, 95% CI = 0.43–0.45,
P < 0.001) (Table 2). Figures 3E and 3F display the HRs of death for
overall and cancer-specific survival after stratification for the year of
diagnosis. Palliative primary cancer resection was consistently pro-
tective for survival over time with HRs ranging between 0.37 (95%
CI = 0.32–0.42) and 0.47 (95% CI = 0.42–0.52) for overall survival
and 0.36 (95% CI = 0.32–0.42) and 0.47 (95% CI = 0.42–0.52) for
cancer-specific survival.
Adjusting for Patients Characteristics
With Propensity Score Matching
Patients undergoing palliative primary tumor resection were
younger, more often female, more often Caucasians, to a higher per-
centage married, had less often rectal cancer, presented more often
with negative/normal CEA values, and had a higher grading score
(Table 1). To further corroborate the findings from univariate and mul-
tivariable Cox proportional hazard regression analyses, a propensity
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FIGURE 3. Survival trend for patients with metastatic colorectal cancer with and without primary tumor removal. A and B, Kaplan-
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for patients who did and who did not undergo primary tumor resection. E and F, HRs of death for primary tumor resection for
overall and cancer-specific survival after stratification for the year of diagnosis. An HR of less than 1 indicates a beneficial effect of
primary tumor removal.
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the propensity score distribution for patients with and without primary tumor resection before the matching procedure. Right
upper and right lower panel display the propensity score distribution after full propensity score matching.
score with stratification for the year of diagnosis was performed to op-
timally adjust for the aforementioned listed bias between the 2 groups.
The propensity score for patients with primary tumor resection was
0.72 ± 0.16 compared with 0.44 ± 0.28 for patients without resection
(P < 0.001). After propensity score matching, the score was 0.72 ±
0.16 for patients with and 0.71 ± 0.17 for those without primary
tumor resection. During the propensity score analysis, 360 patients
(146 patients with and 214 patients without palliative primary cancer
resection) were excluded from the analysis because no counterpart
propensity score was identified. Figure 4 displays the distribution of
the propensity scores of the 2 groups prior and after propensity score
matching and weighting. Table 1 summarizes patient characteristics
after propensity score weighting.
Propensity Score Matched Prognostic Factors
for Long-term Survival
When performing a univariable Cox regression analysis after
propensity score matching palliative primary tumor resection per-
sisted to be a significant protective predictor for overall survival (HR
of death = 0.40, 95% CI = 0.39–0.42, P < 0.001) and cancer-specific
survival (HR of death = 0.39, 95% CI = 0.38–0.40, P < 0.001). Table
2 displays the results of the multivariable full Cox regression model
after propensity score matching and weighting.
Sensitivity Analyses
Missing data were replaced by a random survival forest pro-
cedure and confirmed the results stated earlier. In this sensitivity
analysis, the resection of the primary tumor was associated with a
significantly decreased risk for overall survival (HR of death = 0.42,
95% CI = 0.41–0.44, P < 0.001) and cancer-specific survival (HR of
death = 0.42, 95% CI = 0.41–0.43, P < 0.001) in multivariable Cox
regression. The protective effect of palliative primary tumor resec-
tion was confirmed after propensity score matching and weighting for
overall (HR of death = 0.40, 95% CI = 0.39–0.41, P < 0.001) and
cancer-specific mortality (HR of death = 0.39, 95% CI = 0.38–0.40,
P < 0.001).
DISCUSSION
To our knowledge, this is the first population-based analy-
sis comparing overall and cancer-specific survival trends from 1998
through 2009 in a large cohort of stage IV colorectal cancer pa-
tients who did and who did not undergo palliative primary cancer
removal. The present investigation yields 3 key results: First, the
rate of metastatic colorectal patients undergoing primary tumor re-
moval diminished relevantly over the past decade. Second, overall
and cancer-specific survival improved over time both for patients
who did and who did not undergo palliative primary cancer removal.
Third and most importantly, overall and cancer-specific survival re-
main significantly higher in patients undergoing palliative primary
cancer removal, even after adjusting in multivariable or propensity
score analyses. Indeed, the 2 patient subsets who did and who did
not undergo palliative primary tumor removal were similar after the
propensity score weighting, thus substantially decreasing putative
Copyright © 2014 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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confounding (Fig. 4). Nonetheless, some selection bias is likely to
persist despite thorough statistical adjustment in multivariable and
propensity score analyses. However, the dogma that an asymptomatic
primary tumor never should be resected in patients with unresectable
colorectal cancer metastases must be questioned.
The mechanism, through which cancer-specific and overall sur-
vival might be prolonged in patients with metastatic colorectal cancer
undergoing palliative primary tumor removal, remains to be clarified.
Interestingly, a clear survival benefit of primary tumor resection was
demonstrated in 2 randomized controlled trials in metastatic renal-cell
cancer patients.22,23 Two recent attempts of performing a randomized
controlled trial in patients with unresectable metastatic colorectal
disease have prematurely closed due to poor recruiting. The first was
sponsored by University College London Hospitals (NCT01086618)
and the second trial by Colorectal Surgical Society of Australia and
New Zealand (ACTRN12609000680268). A third trial initiated in
Germany (SYNCHRONOUS trial) is still recruiting and the results
are anticipated with great interest.24 Nonetheless, these trials empha-
size the cardinal importance of the research question of the present
investigation.
In contrast to previous SEER database analyses, the rate of
metastatic colorectal cancer patients undergoing palliative primary
tumor resection further diminished in this study.25,26 This behavior
might reflect previous studies demonstrating that leaving the primary
tumor in situ does seldom result into life threatening complications
such as bleeding or complete obstruction.8 On the basis of these find-
ings, the National Comprehensive Cancer Network’s Guidelines rec-
ommend surgery in patients with asymptomatic metastatic colorectal
disease only if performed in a curative attempt.27,28 On the basis of
our findings, however, this recommendation must be questioned as
some selected stage IV colorectal cancer patients may benefit form
primary tumor removal.
Major advances have been made in systemic treatment of
metastatic colorectal cancer. Indeed, 10 years ago, only 2 chemother-
apeutic drugs (5-fluoropyrimidine and irinotecan) were widely
available, whereas the number of agents in the armamentarium has
significantly increased over the past decade. In addition to other
chemotherapeutic drugs such as Oxaliplatin,29 there are anti-VEGF30
and anti-EGFR antibodies31 that nowadays play an important role in
the treatment of metastatic colorectal cancer. Because of the improve-
ment in systemic treatment, we anticipated that the difference in over-
all and cancer-specific survival between the subsets of patients who
did and who did not undergo palliative primary tumor resection would
decrease over time. However—against our a priori hypothesis—our
analysis demonstrates the contrary. Indeed, the HR for overall survival
is 0.44 in patients undergoing cancer-directed surgery in univariate
analyses. This very low HR persisted after adjusting for putative
confounders available in the SEER data set using multivariable and
propensity score analyses and did not relevantly change over time.
There is a heated debate in the medical and surgical oncology com-
munity regarding whether or not an asymptomatic primary tumor
should be removed in patients with unresectable, synchronous col-
orectal cancer metastases.10 Other studies have shown a benefit of
removing the primary tumor first; however, these have been nonran-
domized and thus a relevant selection bias cannot be excluded.11 It is
obvious that patients who are younger, less comorbid, and with less
metastases are more likely to be operated, whereas the older, sicker pa-
tients with many metastatic sites will not undergo surgery. The same
issue is of course true for this study, for which a selection bias must
be anticipated. Although we did risk-adjust using both multivariable
and propensity score analyses, this adjustment was only possible for
known confounders present in the SEER data set. Some remaining
confounding is therefore well possible. However, it seems unlikely
that the large difference in overall and cancer-specific survival found
in our investigation is solely due to unadjusted confounding.
We would like to acknowledge the limitations of this study.
The main drawback of this analysis is the lack of information on
chemotherapeutic drugs or antibodies used, data that cannot be ascer-
tained in the SEER registry. Similarly, information about comorbidi-
ties, performance status, and site and number of metastases are not
available in the SEER database. Finally, it is not deducible from the
SEER database whether the primary tumor was truly asymptomatic.
To which extent these parameters might have influenced the selection
of patients undergoing surgery remains unclear. However, the subset
of stage IV colorectal cancer patients benefitting most from a pri-
mary tumor removal cannot be determined on the basis of the SEER
database. In addition, there is a relevant number of missing values
for certain parameters (eg, nodal status, T-stage), as many patients
did not undergo surgery at all. However, such data are less relevant
in patients with stage IV disease. Despite these limitations, this study
has a variety of strengths. First, the population-based nature of the
registry mirrors the real-world outcomes for patients with metastatic
colorectal cancer and is associated with a high degree of generaliz-
ability. It is key to evaluate to which extend advances in often highly
selected patients in randomized controlled trials have translated into
the overall patient population. Second, our study reports data on a
12-year time period. Third, the large sample size is associated with a
high degree of power.
CONCLUSIONS
This is the first population-based study reporting multivariable
and propensity score–adjusted trends of cancer-specific and overall
survival over 12 years in patients with metastatic colorectal cancer
who did and who did not undergo palliative primary tumor resection.
A statistically significant and clinically relevant survival benefit was
found in patients who underwent primary cancer removal, which per-
sisted from 1998 to 2009. Therefore, the dogma that an asymptomatic
primary tumor never should be resected in patients with unresectable
colorectal cancer metastases must be questioned.
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